Bertrand C. Liang, M.D., M.B.A.
Chief Executive Officer
Dr. Bertrand C. Liang is the Managing and Executive Director of LCC Ventures, an advisory company in the biotech, pharma and venture areas. He was previously Vice Chairman, Paramount Biosciences, LLC, where he led the private equity activities, including licensing, investments and internal development capabilities of the seven global offices, from Shanghai to London. He was President, CEO and Director of Tracon Pharmaceuticals, Inc., an oncology-focused development company located in San Diego; previously, he was Vice President, New Ventures at Biogen Idec. Prior to the merger of the Biogen and Idec companies, he was Vice President, Development, managing the Hematology and Oncology portfolio, including biologics such as Rituxan and Zevalin, as well as small molecules. Subsequent to the merger, he became the Site Head of Development (preclinical and clinical) in San Diego prior to being in the corporate venture capital group, which was partnered with MPM Capital, one of the largest global life science focused funds. Dr. Liang joined Idec from Amgen, where he led the development of various cytokines and proteins, including the clinical development and launch of Neulasta™ (pegfilgrastim), whose sales have reached over $3B since introduction to the market in 2002. Dr. Liang served as study section member as well as section chair (metastatic cancer) of a NCI Organizational Review Group (Brain Tumors), which evaluated all programs within the NCI and set recommendations for future direction of resource allocation for the institute. Dr. Liang serves on the Board of Directors for several companies, including Tracon Pharmaceuticals, Asphelia Pharma, and Pico Pharmaceuticals. Dr. Liang is clinically trained in Neurology and Oncology, with basic science work in molecular genetics and molecular pharmacology. Dr. Liang has held academic positions at the NCI, University of Colorado and University of Vermont, where he was the head of Human Medical Genetics. His previous research involved the role of mitochondria and the mitochondrial genome in the tumorigenic phenotype, translational research in cancer and neurology patients, and patented platform technology work in genomics discovery.

Patrick K. Lucy
Vice President of Business Development
Mr. Lucy played a leadership role on the original team that developed Pfēnex Expression Technology™ and subsequently led the successful commercial launch of the platform in 2004. He has led the negotiation and completion of numerous technology partnering, licensing, manufacturing and collaboration agreements with the federal government and pharmaceutical companies worldwide. Mr. Lucy is experienced in the areas of alliance management, licensing, intellectual property, biopharmaceutical operations, and biopharmaceutical facility design, construction and validation.

Prior to his role in Pfēnex Mr. Lucy was employed by The Dow Chemical Company for nine years in business development roles for the Dowpharma business unit. Mr. Lucy has been in the biotechnology industry for over eighteen years and was previously employed by Collaborative BioAlliance, Inc., Lonza Biologics, Celltech Biologics and Repligen Corporation.

Mr. Lucy holds a B.S. in Biology from Villanova University.

Henry W. Talbot, Ph.D.
Vice President of Research and Operations
Dr. Talbot received his Ph.D. degree from Oregon State University in microbiology. His experience in the biotechnology industry is focused on process development and manufacturing.

Dr. Talbot initially worked in industrial enzyme discovery and fermentation/recovery development at Novo Nordisk (now Novozymes) on the development of novel alpha-amylases, proteases and lipases, where he was Group Leader of Microbiology. He subsequently joined Mycogen Corporation, and served as Director of Fermentation and Manufacturing, leading process development and 150,000 liter manufacturing of insecticidal proteins produced in Pseudomonas fluorescens. In 1998, Mycogen was acquired by The Dow Chemical Company and Dr. Talbot assumed the role of Director of Bioprocessing and later as Site Leader for Dow’s biotechnology facility in San Diego, leading a variety of industrial biotechnology and biopharmaceutical projects as well as site operations.

Charles H. Squires, Ph.D.
Vice President of Discovery and External Partnerships
Dr. Squires received his Ph.D. in biology from Purdue University and was a post-doctoral associate at Cornell University studying microbial gene regulatory mechanisms. Dr Squires held a number of research and leadership positions at Synergen Inc., later acquired by Amgen, in the area of discovery and development of protein pharmaceuticals. Later he joined Energy Biosystems where he led biocatalyst development. He joined The Dow Chemical Company in San Diego in 1999 as senior director for biotechnology research and development. During the period 1999-2004 he led the development of the Pseudomonas fluorescens gene expression platform for its application to the production of human pharmaceuticals and vaccines. In 2004 he assumed the R&D leadership upon the launch of the Pfēnex Expression Technology™ by the Dowpharma business unit. At Pfēnex Inc. Dr. Squires leads discovery research as well as the Company’s research partnerships with both pharmaceutical developers and governmental agencies.